Summary of COVID-19 zunsemetinib studies
Hide extended summaries
RCT 20 hospitalized patients showing no significant difference in outcomes with ATI-450 (zunsemetinib).
Jun 2025, NCT04481685, https://clinicaltrials.gov/study/NCT04481685, https://c19p.org/gan
1. Gan et al., A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19
20 patient zunsemetinib late treatment RCT: no change in mortality (p=1) and 25% higher progression (p=1).RCT 20 hospitalized patients showing no significant difference in outcomes with ATI-450 (zunsemetinib).
Jun 2025, NCT04481685, https://clinicaltrials.gov/study/NCT04481685, https://c19p.org/gan
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.